ItalianoOMARINI, Claudia
Dettaglio
OMARINI, Claudia
Dipartimento di Scienze Biomediche, Metaboliche e Neuroscienze
Pubblicazioni
Risultati 1 - 20 di 51 (tempo di esecuzione: 0.001 secondi).
| Titolo | Data di pubblicazione | Autore(i) | |
|---|---|---|---|
| 1 | Axillary Ectopic Carcinoma of the Breast. Report of Two Cases with Different Clinical Presentation and Review of the Literature. | 2019 | D'Onofrio, Raffaella; Piacentini, Federico; Combi, Francesca; Omarini, Claudia; Luca, Moscetti; Antonella, Drago; Andreotti, Alessia; Rovesti, Giulia; Enza, Palma; Anna, Gambini; Papi, Simona; Tazzioli, Giovanni |
| 2 | Breast cancer follow-up: a national survey of current clinical practice by the centers of Italian Oncological Group of Clinical Research (GOIRC). | 2019 | Omarini, Claudia; Piacentini, Federico; Frassoldati, Antonio; Musolino, Antonino; Dominici, Massimo; Moscetti on behalf of GOIRC, Luca |
| 3 | Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone, do it! | 2020 | Omarini, C.; Maur, M.; Luppi, G.; Narni, F.; Luppi, M.; Dominici, M.; Longo, G.; Piacentini, F. |
| 4 | Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. | 2018 | Pozzi, S.; Belletti, L.; Cortesi, L.; Moscetti, L.; Omarini, C.; Piacentini, F.; Toss, A.; Caputo, Francesco; Greco, S.; Isca, C.; Napolitano, M.; Tarantino, V.; Malinverni, C.; Checchi, Eleonora; Mascia, Maria Teresa; Cascinu, S |
| 5 | Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. | 2016 | Omarini, Claudia; Caprera, Cecilia; Manfredini, Samantha; Caggia, Federica; Guaitoli, Giorgia; Filieri, Maria Elisabetta; Moscetti, Luca; Bettelli, Stefania Raffaella; Kaleci, Shaniko; Cascinu, Stefano; Piacentini, Federico |
| 6 | Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. | 2018 | Omarini, C; Bettelli, S; Caprera, C; Manfredini, S; Caggia, F; Guaitoli, G; Moscetti, L; Toss, A; Cortesi, L; Kaleci, S; Maiorana, A; Cascinu, S; Conte, Pf; Piacentini, F |
| 7 | Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. | 2019 | Barbolini, M; Omarini, C; Viola, L; Isca, C; Marchi, I; Caggia, F; Barbieri, E; Toss, A; Cortesi, L; Dominici, M; Piacentini, F. |
| 8 | Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials | 2020 | Omarini, C.; Piacentini, F.; Sperduti, I.; Barbolini, M.; Isca, C.; Toss, A.; Cortesi, L.; Barbieri, E.; Dominici, M.; Moscetti, L. |
| 9 | Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status | 2017 | OMARINI, Claudia; KALECI, SHANIKO; GUAITOLI, GIORGIA; BETTELLI, Stefania Raffaella; Cecilia, Caprera; MANFREDINI, SAMANTHA; CAGGIA, Federica; BASCHIERI, MARIA CRISTINA; Luca, Moscetti; MAIORANA, Antonino; CASCINU, Stefano; PIACENTINI, Federico |
| 10 | Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. | 2017 | Omarini, C; Kaleci, S; Guaitoli, G; Bettelli, S; Caprera, Cecilia; Manfredini, S; Caggia, F; Baschieri, Cristina; Moscetti, Luca; Maiorana, A; Cascinu, S; Piacentini, F |
| 11 | Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. | 2019 | Omarini, C; Bettelli, S; Caprera, C; Manfredini, S; Barbolini, M; Moscetti, L; Isca, C; Toss, A; Barbieri, E; Cortesi, L; Kaleci, S; Maiorana, A; Tazzioli, G; Cascinu, S; Piacentini, F |
| 12 | Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting | 2020 | Pizzuti, L; Krasniqi, E; Barchiesi, G; Della Giulia, M; Izzo, F; Sanguineti, G; Marchetti, P; Mazzotta, M; Giusti, R; Botticelli, A; Gamucci, T; Natoli, C; Grassadonia, A; Tinari, N; Iezzi, L; Tomao, S; Tomao, F; Tonini, G; Santini, D; Astone, A; Michelotti, A; De Angelis, C; Mentuccia, L; Vaccaro, A; Magnolfi, E; Gelibter, A; Magri, V; Cortesi, E; D'Onofrio, L; Cassano, A; Rossi, E; Cazzaniga, M; Moscetti, L; Omarini, C; Piacentini, F; Fabbri, Ma; Scinto, Af; Corsi, D; Carbognin, L; Bria, E; La Verde, N; Samaritani, R; Garufi, C; Barni, S; Mirabelli, R; Sarmiento, R; Veltri, E; D'Auria, G; Paris, I; Giotta, F; Lorusso, V; Cardillo, F; Landucci, E; Mauri, M; Ficorella, C; Roselli, M; Adamo, V; Ricciardi, Grr; Russo, A; Berardi, R; Pistelli, M; Fiorio, E; Cannita, K; Sini, V; D'Ostilio, N; Foglietta, J; Greco, F; Zamagni, C; Garrone, O; Di Cocco, B; Baldini, E; Livi, L; Desideri, I; Meattini, I; Sarobba, G; Del Medico, P; De Tursi, M; Generali, D; De Maria, R; Risi, E; Ciliberto, G; Sperduti, I; Villa, A; Barba, M; Di Leo, A; Vici, P. |
| 13 | Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL study. | 2019 | A Fabbri, M; Botticelli, A; Omarini, C; Cretella, E; Fabi, A; Alesini, D; Pizzuti, L; Piesco, G; Vaccaro, A; Atzori, F; Piacentini, F; Moscetti, L; Orlandi, A; Sini, V; Mercanti, A; L Framarino, M; Persano, M; Ceccherini, R; M Ruggeri, E |
| 14 | Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? | 2018 | Toss, A.; Venturelli, M.; Sperduti, I.; Isca, C.; Barbieri, E.; Piacentini, F.; Omarini, C.; Cortesi, L; Cascinu, Stefano; Moscetti, L. |
| 15 | Endocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trial | 2019 | Omarini, C; Sperduti, I; Barbolini, M; Isca, C; Bocconi, Alessandro; Toss, A; Cortesi, L; Barbieri, E; Piacentini, F; Cascinu, S; Moscetti, L |
| 16 | ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. | 2018 | Venturelli, M.; Toss, A.; Piacentini, F.; Artuso, L.; Bernardis, I.; Parenti, S.; Tenedini, E.; Omarini, C.; Moscetti., 1; Cascinu, S.; Tagliafico, E.; Cortesi, L. |
| 17 | First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? | 2018 | Toss, A; Venturelli, M; Sperduti, I; Isca, C; Molinaro, E; Barbieri, E; Piacentini, F; Omarini, C; Cortesi, L; Cascinu, S; Moscetti, |
| 18 | First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? | 2018 | Toss, A.; Venturelli, Marta; Sperduti, I.; Isca, Chrystel; Barbieri, Elena; Piacentini, F.; Omarini, C.; Cortesi, L.; Cascinu, S.; Moscetti, L. |
| 19 | First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis | 2019 | Toss, A.; Venturelli, M.; Sperduti, I.; Molinaro, E.; Isca, C.; Barbieri, E.; Piacentini, F.; Omarini, C.; Cortesi, L.; Cascinu, S.; Moscetti, L. |
| 20 | Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications | 2018 | Toss, Angela; Piacentini, Federico; Cortesi, Laura; Artuso, Lucia; Bernardis, Isabella; Parenti, Sandra; Tenedini, Elena; Ficarra, Guido; Maiorana, Antonino; Iannone, Anna; Omarini, Claudia; Moscetti, Luca; Cristofanilli, Massimo; Federico, Massimo; Tagliafico, Enrico |
Copyright © 2021